After following Edgewise closely, what stands out is the rare alignment among pipeline differentiation, development discipline, and capital allocation.

Our original 2025 thesis was built around two assets: sevasemten for Becker/Duchenne muscular dystrophy and EDG-7500 for hypertrophic cardiomyopathy, or HCM. In early June 2026, Edgewise agreed to sell the muscular dystrophy franchise to Servier for up to $2.65 billion. The transaction crystallizes value for sevasemten, strengthens the balance sheet through non-dilutive financing, and lets shareholders retain exposure to the higher-upside cardiovascular franchise.

Our first proprietary insight is that EDG-7500 should not be valued as a conventional cardiac myosin inhibitor, or CMI. CMIs such as mavacamten and aficamten have demonstrated efficacy in HCM, but their pharmacology is a double-edged sword: improved diastolic relaxation comes with negative inotropy. Patients may benefit from improved relaxation, but must also bear the risk of impaired systolic function and, in vulnerable patients, heart failure. This creates an inherently narrow therapeutic window.

That window limits CMIs in three ways. First, mavacamten requires repeated echocardiographic monitoring under a Risk Evaluation and Mitigation Strategy, or REMS, which is burdensome for many community cardiology practices. Second, mavacamten can only be used above specified ejection-fraction thresholds, while trials have generally enrolled patients with strong systolic reserve. Third, the limitation is sharper in nonobstructive HCM, or nHCM, where patients often have less room to tolerate negative inotropy. Although aficamten’s Phase 3 ACACIA-HCM study was statistically positive in nHCM, the KCCQ benefit was only about 3 points, limiting both clinical and commercial relevance.

EDG-7500’s core pharmacologic advantage is that it may deliver diastolic benefit without meaningful systolic impairment. If sustained in larger datasets, this would address the central limitation of CMIs and support a next-generation HCM profile. To date, EDG-7500 has been studied in more than 100 healthy volunteers and patients, with no meaningful LVEF drop signal. In Phase 2 Part B/C studies, EDG-7500 showed dose-dependent benefit across LVOT gradient, NT-proBNP, diastolic parameters, symptoms, and functional scores. In nHCM, despite small sample size, the KCCQ signal appears materially stronger than aficamten’s.

Our second proprietary insight is that the market’s interpretation of the atrial fibrillation, or AF, signal is too crude. The market saw 4 AF cases among 29 patients in an early HCM cohort and treated this as direct atrial or electrophysiologic toxicity. We think the broader pathophysiologic context supports a different model: in an HCM population already at elevated AF risk, flat-dose EDG-7500 may have produced a strong acute hemodynamic effect that triggered AF in susceptible patients.

The evidence fits this model. HCM itself is a high-AF-risk disease. Early proof-of-concept studies washed out beta blockers and calcium-channel blockers, both of which suppress atrial automaticity. EDG-7500 was initially given directly at a relatively high target dose, and rapid hemodynamic change in a stiff, hypertrophied heart can plausibly increase arrhythmia vulnerability. Finally, there is no evidence to date of chronic atrial toxicity; if anything, in a cardiomyopathy swine model, longer-term EDG-7500 treatment reduced atrial size, a signal directionally consistent with favorable remodeling.

Based on this model, the company’s Part D adjustments are rational: lower starting dose, slower titration, and ambulatory rhythm monitoring. These changes are designed to turn an active molecule into a clinically usable product by engineering around acute hemodynamic perturbation.

Our third proprietary insight is that EDG-15400 gives Edgewise a credible HFpEF option. HFpEF and HCM share diastolic dysfunction as a central pathophysiologic feature, while heart failure patients are unlikely to tolerate meaningful LVEF decline. That makes CMIs poorly suited for HFpEF, but leaves room for a non-negative-inotropic cardiac modulator. EDG-15400 remains in Phase 1 and has not yet disclosed clinical data, but if the mechanism translates, its strategic value could exceed that of a standard follow-on molecule.

Our fourth proprietary insight is management quality. Edgewise’s prior work in Becker muscular dystrophy demonstrated real clinical craft: natural history work to identify faster-progressing subgroups, testing NSAA in proof-of-concept studies, high rollover into extension studies, and disciplined pivotal-trial design. The same style is now visible in cardiology. The company is asking the right product-building questions: how to titrate, how to fit titration into workflow, how to avoid acute hemodynamic overshoot, and which endpoints map to physician decision-making.

Capital allocation reinforces the point. The neuromuscular and cardiology franchises had limited operational synergy. By selling a pre-pivotal-readout asset at an attractive price, Edgewise avoided a binary event, strengthened its balance sheet, and focused the company on the larger cardiovascular opportunity.